| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Cimicifugoside H-1 targets bone metabolism, specifically inhibiting bone resorption. It shows protective function to cerebral neurons during cerebral ischemia. Its mechanism may involve inhibition of osteoclast activity or modulation of bone remodeling pathways.
|
|---|---|
| ln Vitro |
In vitro, Cimicifugoside H-1 inhibits bone resorption. It is a cyclolanostanol xyloside and a major constituent of C. foetida extract. It shows protective function to cerebral neurons during cerebral ischemia. It is isolated and purified by chromatographic methods.
|
| ln Vivo |
In vivo, Cimicifugoside H-1 inhibits bone resorption and ovariectomy-induced bone loss. It shows protective function to cerebral neurons during cerebral ischemia. It has potential for treating osteoporosis and cerebral ischemia.
|
| Enzyme Assay |
Cell-free assays for Cimicifugoside H-1: bone resorption inhibition is assessed by measuring osteoclast activity in cell-free systems. The compound is incubated with osteoclasts or bone resorption markers, and activity is measured. Neuroprotective activity is assessed by measuring protection against ischemia-induced damage in cell-free systems.
|
| Cell Assay |
Cellular assays for Cimicifugoside H-1: osteoclasts or neuronal cells are cultured and treated with Cimicifugoside H-1 at concentrations of 0.1-100 µM for 24-72 hours. Osteoclast activity is assessed by measuring TRAP activity or bone resorption pit formation. Neuronal cell viability is assessed by MTT assay under ischemic conditions.
|
| Animal Protocol |
In vivo animal studies for Cimicifugoside H-1: animal models of osteoporosis (e.g., ovariectomized rats) and cerebral ischemia (e.g., middle cerebral artery occlusion) are used. Animals are administered Cimicifugoside H-1 orally or intraperitoneally at doses of 10-50 mg/kg. Bone mineral density, bone histomorphometry, and neurological function are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Cimicifugoside H-1: as a glycoside (molecular weight 616.78), it may have limited oral bioavailability. It is likely metabolized by intestinal glycosidases. Tissue distribution and elimination pathways require further investigation. Storage: 2-8°C, protected from light.
|
| Toxicity/Toxicokinetics |
Toxicity of Cimicifugoside H-1: comprehensive toxicity data are limited. It is for research use only and not approved for clinical use. Standard laboratory safety precautions should be followed.
|
| References |
|
| Additional Infomation |
It has been reported that cimicifuga foetida, cimicifuga rhizome, and other organisms with relevant data all contain cimicifuga foetida. See also: Black cimicifuga (partial).
Cimicifugoside H-1 is a research compound with potential applications in osteoporosis and cerebral ischemia research. It is a cyclolanostanol xyloside from C. foetida. No clinical trials or FDA approvals have been reported. |
| Molecular Formula |
C35H52O9
|
|---|---|
| Molecular Weight |
616.78
|
| Exact Mass |
674.367
|
| CAS # |
163046-73-9
|
| PubChem CID |
15241163
|
| Appearance |
White to off-white solid
|
| Density |
1.31±0.1 g/cm3 at 760 mmHg
|
| Boiling Point |
748.9±60.0 °C at 760 mmHg
|
| Melting Point |
260-262 °C
|
| Source |
Originated from plants: Ranunculaceae Cimicifuga foetida Linn.
|
| LogP |
2.633
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
44
|
| Complexity |
1290
|
| Defined Atom Stereocenter Count |
14
|
| SMILES |
C[C@H](CC(=O)[C@H]1C(C)(C)O1)[C@H]2C(=O)C[C@@]3(C)C4=CC[C@H]5C(C)(C)[C@H](CC[C@]65C[C@@]46[C@H](C[C@]23C)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O
|
| InChi Key |
PYBFXJMIKJNNAJ-GLWILYKISA-N
|
| InChi Code |
InChI=1S/C35H52O9/c1-17(12-18(36)28-31(4,5)44-28)25-19(37)13-32(6)22-9-8-21-30(2,3)24(43-29-27(41)26(40)20(38)15-42-29)10-11-34(21)16-35(22,34)23(39)14-33(25,32)7/h9,17,20-21,23-29,38-41H,8,10-16H2,1-7H3/t17-,20-,21+,23+,24+,25+,26+,27-,28+,29+,32+,33-,34-,35+/m1/s1
|
| Chemical Name |
(1S,3R,6S,8R,12R,15R,16R,18S)-15-[(2R)-4-[(2R)-3,3-dimethyloxiran-2-yl]-4-oxobutan-2-yl]-18-hydroxy-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxypentacyclo[9.7.0.01,3.03,8.012,16]octadec-10-en-14-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~81.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (2.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6213 mL | 8.1066 mL | 16.2132 mL | |
| 5 mM | 0.3243 mL | 1.6213 mL | 3.2426 mL | |
| 10 mM | 0.1621 mL | 0.8107 mL | 1.6213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
